Entecavir resistance in a patient with treatment-naive HBV: A case report.
PMID: 33903819
2021
Molecular and clinical oncology
Discussion: There were 8 mutations in the RT region, rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V and rtM309K that were significantly associated with the progression of HCC in treatment-naive patients.
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Discussion: In another case in this study, the patient experienced viral breakthrough after 22 months of TDF monotherapy with the mutant HBV bearing mutation pattern of A181T + F221Y.
Discussion: In this study, F221Y was observed in cases not only under ADV therapy but also under LAM treatment (Table 4).
Discussion: Notably, in present study, the mutation pattern of A181T associated with F221Y was observed in one case after 22 months of TDF monotherapy with virological and biochemical breakthrough.
Discussion: reported F221Y was detected in one case suffering viral breakthrough under TDF monotherapy following an initial unsuccessful LAM and ADV combination therapy.
Discussion: reported that an combined mutation pattern of L80M
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Method: Overall, eight mutations in the RT region, namely rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V, and rtM309K, are significantly related to liver disease progression.
Method: Those results were consistent with the report of Li et al, which identified the rt PMID: 30080852
2018
PLoS neglected tropical diseases
Introduction: Virological breakthrough on TDF therapy has been reported in two patients harbouring rtS78T/sC69 mutations, and in another patient with multi-site polymerase mutations; rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rtS223A, rtT184A/L, rtR153Q, and
F221Y mutation in hepatitis B virus reverse transcriptase is associated with hepatocellular carcinoma prognosis following liver resection.
Abstract: rtF221Y was also an independent risk factor for poor overall survival rates (HR=2.557; 95% CI, 1.344-4.866; P=0.004).
Abstract: As a result, rtF221Y was identified as a risk factor for poor prognosis and may be a potential viral marker for predicting prognosis in HCC.
Abstract: The rtF221Y variation and a tumor size >8 cm were found to be independent risk factors for the postoperative recurrence of HCC, with hazard ratios of 2.345 (95% CI, 1.391-3.953; P=0.001) and 1.838 (95% CI, 1.069-3.161; P=0.028), respectively.
Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B.
Abstract: T54N, L80I/V, I91L/V, L180M, M204I/V, Q215P/S, and F221Y/S showed the highest number of mutations in all groups with different frequencies.
Result: F221Y/S was highest in groups I and IV, at 25 and 19.2%, respectively.
Result: Group I: In addition to the nine amino acid substitutions that related to LAM resistance, F221Y/S, which is related to ADV resistance, also was found in the patients in this group, who only received LAM (Table 2).
Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method.
PMID: 24630522
2014
Diagnostic microbiology and infectious disease
Abstract: However, NAr mutations found in 6 isolates (37.5%) involved 7 positions including rtL91I, rtT128I, rtQ215P, rtF221Y, rtN238D, rtC256S, and rtI266G.
Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy.
Abstract: However, this patient experienced virological breakthrough under TDF with a HBV strain bearing rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rtS223A, rtT184A/L, rtR153Q, and rtV191I combined mutations without rtA194T mutation.
Novel point and combo-mutations in the genome of hepatitis B virus-genotype D: characterization and impact on liver disease progression to hepatocellular carcinoma.
Result: The L213I mutation (TTA to ATG) in surface leads to F221Y and A222T dual mutations in reverse transcriptase (RT) dom
Table: F221Y
Discussion: One point mutation L213I observed in the overlapping surface and polymerase gene (F221Y/A222T) in combination with classical BCP mutations A1762T/G1764A showed association with HCC in HBeAg positive patient (Figure 1).
Subgenotypes and mutations in the s and polymerase genes of hepatitis B virus carriers in the West Bank, palestine.
HBV mutation literature information.
PMID: 
2021
Molecular and clinical oncology
Browser Board
Co-occurred Entities
Filtrator
ViMRT